Synageva Biopharma Corp and to-BBB to collaborate on brain drug delivery for rare diseases
Synageva BioPharma Corp. and to-BBB technologies BV have entered into a research collaboration to evaluate the potential of transporting therapeutic proteins across the blood-brain barrier into the central nervous system (CNS). The blood-brain barrier, a protective filter for the CNS, can be an obstacle for protein therapeutics and prevent these treatments from reaching their site of action within the CNS. A number of rare diseases that could benefit from protein therapeutics have a CNS component and require the therapies to be transported across the blood-brain barrier. This research collaboration will be the basis for a development program for therapies for multiple such rare diseases, including Lysosomal Storage Diseases (LSDs).
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.